Dr. Dinesh Srinivasan serves as Vice President, Strategic Portfolio Management at Thryv Therapeutics, bringing extensive experience across drug discovery, translational research, and clinical development in both biotech and pharmaceutical settings.

At Thryv, Dr. Srinivasan leverages his expertise in leading cross-functional project teams, advancing preclinical and clinical-stage assets, and contributing to multiple Investigational New Drug (IND) submissions and Phase 2 clinical studies to optimize and strengthen the company’s R&D portfolio.

Prior to joining Thryv, Dr. Srinivasan held senior leadership roles, including Vice President of Translational Sciences at First Wave Biopharma and Director at Anthera Pharmaceuticals, where he led translational research efforts, supported clinical development programs, and managed external partnerships.

Earlier in his career, Dr. Srinivasan led discovery and translational programs at Hoffmann-La Roche, overseeing laboratory teams, external collaborations, and non-clinical studies across multiple target classes and therapeutic areas.

Dr. Srinivasan holds a PhD in Pharmacology and Toxicology from the University of Arizona and a Mini-MBA in Business Administration from Rutgers University.